Press releases

No cases of moderate or severe paravalvular aortic regurgitation at one year

Data will focus on areas of significant unmet patient need, including Coronary Artery Disease and Aortic Valve Disease

Boston Scientific will participate in the upcoming healthcare conference on September 17, 2014 in London

Acquisition allows Boston Scientific to offer a more complete portfolio of solutions to treat challenging vascular conditions

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure

Boston Scientific will participate in the healthcare conference on September 8 in New York

Companies reach agreement to develop a new and differentiated FFR guidewire and next generation Boston Scientific Rotablator™ RotaWire™

"We had a strong second quarter, delivering balanced growth across our divisions," said CEO Mike Mahoney

Innovative technology adds to company's leading portfolio of treatment options for Coronary Artery Disease

Easy to use imaging system to support planned intravascular ultrasound and fractional flow reserve products